Clinical trials: Hepatitis C, Chronic
Hepatitis C, Chronic
Gilead Sustained Virologic Response (SVR) Registry
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV)…
- Trial name
- NCT01457755
- Where
- 325 sites in United States, Australia and 15 more
- Volunteers
- 6,625 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
- Trial name
- NCT00664625
- Testing
- BMS-791325
- Where
- 6 sites in United States, Argentina
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02378935
- Testing
- VOX, SOF/VEL, RBV
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 205 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
- Trial name
- NCT01511432
- Testing
- telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Purpura, Thrombocytopaenic, Idiopathic
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems.
- Trial name
- NCT00359463
- Testing
- eltrombopag
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
This single arm study will assess the safety of NeoRecormon in the correction of anemia in patients with chronic hepatitis C who are being treated with Pegylated interferon + ribavirin combination therapy.
- Trial name
- NCT00560274
- Testing
- Pegasys, Ribavirin, epoetin beta [NeoRecormon]
- Where
- 24 sites in France
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C…
- Trial name
- NCT01853254
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
- Trial name
- NCT01225380
- Testing
- GS-9190, GS-9256, Pegasys®
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 324 people
- Sponsor
- Gilead Sciences
Hepatitis C, Hepatitis C, Chronic
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard…
- Trial name
- RE-CHUT (NCT00725842)
- Testing
- Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01858766
- Testing
- SOF, VEL, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 379 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks…
- Trial name
- NCT00418054
- Testing
- Nitazoxanide plus peginterferon alfa-2b, Peginterferon alfa-2b
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis C
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with…
- Trial name
- NCT01310205
- Testing
- SCV-07
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- SciClone Pharmaceuticals
Hepatitis C, Chronic
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
- Trial name
- NCT00035945
- Testing
- ISIS 14803
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatitis C, Chronic, Hepatitis C
An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)
This is an observational study of patients undergoing treatment with PegIntron and Rebetol for chronic hepatitis C in clinical practice in Belgium. Treatment will not be administered as part of the study.
- Trial name
- PEGIMPACT (NCT00704756)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
This study is being done to evaluate the efficacy and safety of the drug combination grazoprevir (GZR; MK-5172) + elbasvir (EBR; MK-8742) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection and…
- Trial name
- NCT02115321
- Testing
- Grazoprevir, Elbasvir, MK-5172A
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC